BPC-157, TB-500 and KPV: The FDA Compounding Decision, Explained

If you have tried to buy BPC-157 from a licensed provider recently, you may have noticed something odd: some clinics sell it freely, and others tell you they can't. Both are describing the same rule. This page explains what that rule is, what changed in July 2026, and what has not changed yet.

The one thing to understand first

Compounding pharmacies in the United States cannot use any bulk ingredient they like. Under section 503A of the Food, Drug, and Cosmetic Act, a substance that is not an approved drug generally has to appear on FDA's 503A Bulks List before a pharmacy can lawfully compound with it.

None of the seven peptides below is on that list today. That is the whole reason a compliant clinic will decline to sell you BPC-157 while a less careful one ships it.

What happened in July 2026

FDA's Pharmacy Compounding Advisory Committee — the panel that advises the agency on exactly this question — met on 23 and 24 July 2026 and took up seven peptides for possible addition to the list. Here is the agenda as FDA published it, including the specific medical use the agency evaluated each substance for.

That third column is worth a pause. FDA evaluated BPC-157 as a treatment for ulcerative colitis — not for tendon repair, gut healing or injury recovery, which is what it is actually marketed and sold for. The evidence the agency reviewed was the evidence for the nominated use, and the nominated use is not the one on the vendor pages.

FDA's own scientists recommended against all seven

This is the part that gets left out of most summaries, and it is stated in plain language in FDA's own presentation slides. For each of the seven substances, the agency's recommendation slide reads the same way:

> "FDA is proposing that BPC-157 (free base) and BPC-157 acetate NOT be included on the 503A Bulks List²."

The identical sentence appears for KPV, for TB-500, for MOTS-c², and for emideltide, epitalon and semax³. Seven substances, seven recommendations against.

Why FDA said no to BPC-157 specifically

The agency's reasoning is worth reading in full, because it is more specific than "not enough evidence."

It could not confirm what the substance even is. FDA's conclusion slides state that both forms are "not well-characterized," citing "inconsistent naming conventions that do not follow established chemical nomenclature standards" and a "lack of certain critical characterization data (impurities, aggregates, bioburden, and bacterial endotoxins)," plus a "potential for immunogenicity when formulated in an injectable or nasal spray dosage form"².

The human evidence is one small conference abstract. FDA identified a single trial — 53 subjects with mild to moderate ulcerative colitis, given BPC-157 as a rectal enema or placebo for two weeks. Its own review notes that interpretation "is limited by the lack of details provided in the meeting abstract and the exploratory nature of the study"².

And the routes people actually use were never studied. In FDA's words, the agency "did not identify any studies that administered BPC-157 via the oral, SC, nasal" routes². BPC-157 is sold almost exclusively as a subcutaneous injection or a nasal spray. There is no human study of either.

So what did the committee decide?

The committee voted on each substance, and — reported widely, though FDA has not yet published minutes — went against its own staff on most of them, recommending the majority for inclusion.

We are not printing the vote counts here yet. Every source currently circulating those numbers is a peptide vendor or a search-optimized blog, and FDA's minutes are not out. When the minutes or the Federal Register confirm them, this page gets the numbers and a new date. That is a deliberately slower answer than you will find elsewhere, and it is the honest one.

What has actually changed for a buyer: nothing, yet

Here is the part that matters most, and it is true regardless of how the votes went.

A committee recommendation is not a rule. The Pharmacy Compounding Advisory Committee advises FDA; it does not set policy. For any of these substances to become lawfully compoundable, FDA has to complete formal rulemaking — a process that historically takes many months to a couple of years, and which the agency is free to decline.

Until that finishes, the legal position is unchanged: these substances are not on the 503A Bulks List, and there is no lawful basis for a pharmacy to compound them.

You can watch that play out on providers' own websites. One telehealth clinic we track states it directly: CJC-1295 and ipamorelin "are not currently offered through YourHealthRx: their nominations were withdrawn and they are not on the FDA 503A bulk drug substances list, so they have no current lawful compounding basis." That is a company turning down revenue because of this rule. It is also a useful test: a seller who cannot explain their legal basis for compounding one of these peptides probably does not have one.

What this means if you are shopping right now

The compounds on this page are not in the same position as tirzepatide and semaglutide, whose compounded versions rest on a different and much better-established legal footing. If you are comparing providers for those, our tirzepatide and semaglutide rankings track what each one actually charges.

For BPC-157 itself, our evidence review, dosage guide and side-effect summary cover what the research does and does not show, separately from the regulatory question.

We will update this page when FDA acts.